Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases

CONCLUSION: We found a high prevalence of clinically relevant genomic alterations in BCBM patients, suggesting that tissue acquisition (surgery) and or cerebrospinal fluid (CSF) for CGP in addition to CGP of the primary tumor may be clinically warranted.IMPLICATIONS FOR PRACTICE: We found a high prevalence of clinically relevant genomic alterations in BCBM patients, suggesting that tissue acquisition (surgery) and or cerebrospinal fluid (CSF) for CGP in addition to CGP of the primary tumor may be clinically warranted. In addition, we identified higher positive rates for FDA-approved immunotherapy biomarkers detected by CGP in BCBM patients, opening the possibility for new on-label treatments. Last, we noted limited correlation between TMB and PD-L1 IHC which exemplifies the importance to test with both PD-L1 IHC and CGP for ICPI eligibility of TNBC patients with brain metastases.PMID:34105210 | DOI:10.1002/onco.13855

Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Richard S P Huang James Haberberger Kimberly McGregor Douglas A Mata Brennan Decker Matthew C Hiemenz Mirna Lechpammer Natalie Danziger Kelsie Schiavone James Creeden Ryon P Graf Roy Strowd Glenn J Lesser Evangelia D Razis Rupert Bartsch Athina Giannoudis Source Type: research